MAPS-2 (IFCT-1501): Nivolumab ± Ipilimumab in Recurrent Malignant Pleural Mesothelioma

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 671 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings